Respiratory Medicine
Volume 95, Issue 1 , Pages 83-89, January 2001

Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.

  • D.B. PRICE

      Affiliations

    • University of Aberdeen, U.K.
    • ,
  • R.H. BEN-JOSEPH

      Affiliations

    • Merck & Co., Inc. Whitehouse Station, NJ, U.S.A.
    • ,
  • Q. ZHANG

      Affiliations

    • Merck & Co., Inc. Whitehouse Station, NJ, U.S.A.

Received 9 June 2000; accepted 25 October 2000.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0954-6111(00)91006-0

doi:10.1053/rmed.2000.1006

Refers to erratum:

  • Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Volume 95, pp. 83-89

    D.B. PRICE, R.H. BEN-JOSEPH, Q. ZHANG
    Respiratory Medicine July 2001 (Vol. 95, Issue 7, Page 627)

Respiratory Medicine
Volume 95, Issue 1 , Pages 83-89, January 2001

Article Tools